|Bid||329.70 x 226100|
|Ask||320.60 x 394900|
|Day's Range||316.40 - 326.30|
|52 Week Range||293.10 - 645.00|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.08 (2.59%)|
|1y Target Est||N/A|
Mediclinic International Plc, reported a 4% fall in full-year core profit on Thursday, in line with market expectations, hit by regulatory changes for its Swiss business. Mediclinic, which also has operations in southern Africa and the Middle East, has faced stricter regulations in Switzerland that have hobbled growth and put pressure on margins. "The operating performance was impacted by the lower contribution from Hirslanden (Swiss), offset by an improved performance in the second half of the financial year from Mediclinic Southern Africa and Mediclinic Middle East," the firm said in a statement.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or...
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Mediclinic International plc (LSE:MDC), with a market capitalization of UK£4.67B, rarely draw their attention from the investingRead More...